{
    "clinical_study": {
        "@rank": "111029", 
        "arm_group": [
            {
                "arm_group_label": "Inactivated HAV vaccine", 
                "description": "Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose"
            }, 
            {
                "arm_group_label": "Attenuated alive HAV vaccine", 
                "description": "Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose"
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum samples were taken from subjects."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this follow-up study is to evaluate the five-year immune persistence of one\n      injection of inactivated and attenuated alive hepatitis A vaccine in healthy children."
        }, 
        "brief_title": "The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis A", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A"
            ]
        }, 
        "detailed_description": {
            "textblock": "In the previous double-blind, randomized, phase IV clinical trial in 2008, 300 healthy\n      Chinese children aged 18 to 35 months old were administered with one dose of  inactivated\n      and attenuated alive hepatitis A vaccine. Series of serum samples were taken for\n      immunogenicity and immune persistence evaluation. Safety observations were performed after\n      vaccination. This trial was also approved by Tianjin CDC Biomedical Ethics Committee in\n      2008.\n\n      This study is the fifth-year follow-up research for the previous clinical trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All subjects who received inactivated or attenuated alive HAV vaccine in the previous\n             trial\n\n        Exclusion Criteria:\n\n          -  Subjects who refused to continue in the follow-up study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Months", 
            "minimum_age": "18 Months", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Healthy Chinese children aged 18 to 35 months old"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002065", 
            "org_study_id": "PRO-HA-4013 version 2.0"
        }, 
        "intervention": [
            {
                "arm_group_label": "Inactivated HAV vaccine", 
                "description": "Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose", 
                "intervention_name": "Inactivated HAV vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Attenuated alive HAV vaccine", 
                "description": "Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose", 
                "intervention_name": "Attenuated alive HAV vaccine", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "hepatitis A", 
            "inactivated hepatitis A vaccine", 
            "attenuated alive hepatitis A vaccine", 
            "immune persistence"
        ], 
        "lastchanged_date": "December 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "zip": "300000"
                }, 
                "name": "Tianjin center for disease prevention and control"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Phase IV, Open-labelled, Follow-up Study to Evaluate the Five-year Immune Persistence of One Injection of Inactivated or Attenuated Alive Hepatitis A Vaccine in Healthy Chinese Children", 
        "overall_official": {
            "affiliation": "Tianjin Center for Diseases Control and Prevention", 
            "last_name": "Zhi-Lun Zhang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "to evaluate the immune persistence of anti-HAV antibodies in serum", 
            "measure": "The geometric mean concentration (GMC) of anti-hepatitis A virus (HAV) antibodies in serum 60 months after vaccination", 
            "safety_issue": "No", 
            "time_frame": "60 months after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002065"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sinovac Biotech Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sinovac Biotech Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}